Search

News & Events

The Telethon Institute for Child Health Research today announced a new study investigating a vaccine to prevent infection of Human Papilloma Virus (HPV).

Research

Cervical cancer mortality has been reduced in Australia because of effective screening programs, but there are still about 800 new cases...

Research

Pneumococcal conjugate vaccines (PCV) reduced the risk of respiratory syncytial virus (RSV) in a randomized clinical trial. We aimed to assess the real-world effectiveness of PCV on RSV-hospitalizations among Western Australian infants.

Research

Individuals who receive allogeneic hematopoietic cell transplant (allo-HCT) are immunocompromised and at high risk of pneumococcal infections, especially in the months following transplant. This study evaluated the safety and immunogenicity of V114 (VAXNEUVANCE; Merck, Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA), a 15-valent pneumococcal conjugate vaccine (PCV), when given to allo-HCT recipients. 

Research

BCG vaccination and revaccination are increasingly being considered for the protection of adolescents and adults against tuberculosis and, more broadly, for the off-target protective immunological effects against other infectious and noninfectious diseases. Within an international randomized controlled trial of BCG vaccination in healthcare workers (the BRACE trial), we evaluated the incidence of local and serious adverse events, as well as the impact of previous BCG vaccination on local injection site reactions (BCG revaccination).

Research

To evaluate the safety and immunogenicity of V114 [15-valent pneumococcal conjugate vaccine (PCV) containing serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9 V, 14, 18C, 19A, 19F, 22F, 23F, 33F], followed by 23-valent pneumococcal polysaccharide vaccine (PPSV23) 8 weeks later, in children with HIV.

The Infectious Disease Implementation Research Team is a multi-disciplinary group researching the best way to implement infectious disease prevention and treatment strategies to improve the wellbeing of children and teenagers.

Research

We evaluated the frequency of moderate and severe adverse events following coadministration of seasonal influenza vaccine (SIV) versus placebo with COVID-19 vaccines among adults to support practice guidelines. 

News & Events

A new study shows that people living in the Oceania region, including Australia, have the highest risk in the world of dying from rheumatic heart disease.

News & Events

Toddlers will now get an additional whooping cough vaccine to protect them against the potentially deadly disease.

News & Events

Mapping when Respiratory Syncytal Virus (RSV) reaches its seasonal peak will assist how future vaccination programs are carried out.

News & Events

It's that time of year again... Flu vaccine time! Watch Dr Chris Blyth answer commonly asked questions in the video below.

Research

Influenza (commonly known as the flu) is caused by a highly contagious virus spread mainly through coughing and sneezing. An annual flu vaccination is the most effective way to prevent flu outbreaks.

News & Events

More children across Australia are being vaccinated against the flu since funding was expanded and access widened under the National Immunisation Program

Research

Respiratory Syncytial Virus (RSV) causes a significant burden of illness for children under 2 years of age. Nirsevimab, a long-acting monoclonal antibody, was registered for RSV prevention in Australia in 2023. In April 2024, Western Australia (WA) launched the country's first state-wide nirsevimab program for all infants and high-risk children entering their second RSV season. 

Research

Invasive pneumococcal disease remains a major cause of hospitalization and death in Papua New Guinean (PNG) children. We assessed mucosal IgA and IgG responses in PNG infants vaccinated with pneumococcal conjugate vaccine (PCV) followed by a pneumococcal polysaccharide vaccine (PPV) booster.